PAK4 as a potential marker for poor response to immunotherapy in melanoma patients | NeoGenomics Laboratories

Publication date

Fri, 09/09/2022 - 12:00

Category

Year

Subtitle

ESMO 2022

File

ESMO%20poster_2022.pdf (777.99 KB)

Division